TITLE

Tarceva

PUB. DATE
September 2005
SOURCE
Pharmaceutical Representative;Sep2005, Vol. 35 Issue 9, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Highlights the results of a clinical trial of Melville, New York-based OSI Pharmaceuticals Inc. and South San Francisco, California-based Genentech Inc.'s Tarceva (erlotinib). Evidence that Tarceva may extend the lives of patients with advanced nonsmall cell lung cancer; Publication of the of the double- blind, phase III study "The New England Journal of Medicine".
ACCESSION #
18123468

 

Related Articles

  • Genentech Drug Combo a Go.  // Chemical Market Reporter;9/27/2004, Vol. 266 Issue 10, p10 

    Reports on the development of an oncology drug for the treatment of metastatic pancreatic cancer from the partnership between OSI Pharmaceuticals and Genentech Inc. in the U.S. Results of the clinical study of the drug in combination with gemcitabine chemotherapy; Percentage improvement in the...

  • OSI, Genentech Slump on Avastin-Tarceva Miss.  // Bioworld Week;10/13/2008, Vol. 16 Issue 41, p3 

    The article cites a study which shows that Avastin and Tarceva in combination failed in a Phase II trial to improve overall survival of patients with non-small-cell lung cancer (NSCLC). In notes that Avastin was marketed by Genentech Inc., while OSI Pharmaceuticals Inc. marketed Tarceva under a...

  • Tarceva trial fails.  // Long Island Business News (7/1993 to 5/2009);10/10/2008, Vol. 55 Issue 50, p12A 

    The article focuses on the failure of a clinical trial conducted by Genentech Inc. and OSI Pharmaceuticals Inc. on a combination of two cancer drugs to improve survival of patients with lung cancer in New York. According to the two companies, the trial was called BeTa Lung which has met its...

  • Genentech and OSI's Phase III lung cancer study fails endpoint.  // PharmaWatch: Cancer;Nov2008, Vol. 7 Issue 11, p18 

    The article reports on the data released by Genentech Inc. and OSI Pharmaceuticals Inc. regarding the evaluation of the Phase III study of Avastin in combination with Tarceva. It reveals that the combination did not meet its primary endpoint of improving overall survival. According to Gabriel...

  • OSI / Genentech / Roche: Tarceva triumphs again.  // PharmaWatch: Biotechnology;Nov2005, Vol. 4 Issue 11, p4 

    The article focuses on a study regarding the effect of Tarceva drugs in the treatment of cancer in the elderly patients. It has suggested that the Tarceva drug manufactured by OSI Pharmaceuticals Inc., Genentech Inc. and Roche may be particularly beneficial in elderly patients with previously...

  • Tarceva Data Intensify Lung Cancer Competition.  // Bioworld Week;7/20/2009, Vol. 17 Issue 29, p3 

    The article reports that OSI Pharmaceuticals Inc., and partner Genentech Inc., have given a tough blow to their competitor Eli Lilly & Co. by announcing a drug for the treatment of lung cancer. As stated, the EGFR-inhibitor Tarceva (erlotinib) demonstrated a statistically significant overall...

  • Other Cancers News Headlines March 15, 2004--April 14, 2004.  // PharmaWatch: Cancer;May 2004, Vol. 3 Issue 5, p17 

    Presents a roundup of cancer news headlines for the period of March 15, 2004, to April 14, 2004. OSI Pharmaceuticals Inc.'s initiation of a phase II study of the lung cancer drug Tarceva; Uncertainty surrounding SuperGen's Dacogen study; Effectiveness of Ariad's oncology product AP23464 in...

  • Genentech reports encouraging data from Phase III colon cancer trial.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p6 

    The article reports on the result of the international Phase III study conducted by the biotechnology company Genetech Inc. It highlights that the research showed the efficacy and the being commonly used of oral Xeloda plus oxaliplatin in chemotheraphy for colon cancer. Based on the data...

  • Follow up.  // Long Island Business News (7/1993 to 5/2009);6/4/2004, Vol. 51 Issue 24, p5A 

    In the course of any drug trial, there comes a time when hype is replaced by hard data. That moment is approaching for Tarceva, the lead cancer drug of OSI Pharmaceuticals Inc. On June 8, 2004, OSI CEO Colin Goddard will announce the results of a phase III clinical trial for non-small-cell lung...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics